Compare IRTC & BLLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IRTC | BLLN |
|---|---|---|
| Founded | 2006 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2B | 4.6B |
| IPO Year | 2016 | 2025 |
| Metric | IRTC | BLLN |
|---|---|---|
| Price | $116.98 | $89.18 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 13 | 7 |
| Target Price | ★ $197.92 | $126.71 |
| AVG Volume (30 Days) | 648.9K | ★ 779.6K |
| Earning Date | 04-30-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 61.71 | ★ 103.40 |
| EPS | N/A | ★ 0.48 |
| Revenue | ★ $747,138,000.00 | $305,112,000.00 |
| Revenue This Year | $19.60 | $46.29 |
| Revenue Next Year | $15.94 | $30.14 |
| P/E Ratio | ★ N/A | $195.65 |
| Revenue Growth | 26.24 | ★ 99.97 |
| 52 Week Low | $100.85 | $61.96 |
| 52 Week High | $210.01 | $150.44 |
| Indicator | IRTC | BLLN |
|---|---|---|
| Relative Strength Index (RSI) | 46.54 | 33.40 |
| Support Level | $112.65 | $83.59 |
| Resistance Level | $123.44 | $99.29 |
| Average True Range (ATR) | 6.36 | 6.68 |
| MACD | -0.65 | -4.24 |
| Stochastic Oscillator | 5.19 | 1.13 |
iRhythm Holdings Inc is a digital healthcare company that creates trusted solutions that detect, predict, and prevent disease. Its principal business is the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services that it believes allow clinicians to diagnose certain arrhythmias quicker and with greater efficiency than other services that rely on traditional technology. Each Zio System combines an FDA-cleared and CE-marked, wire-free, patch-based, 14-day wearable biosensor that continuously records electrocardiogram (ECG) data with a proprietary, FDA-cleared, CE-marked cloud-based data analytic software to help physicians monitor patients and diagnose arrhythmias.
BillionToOne Inc is a molecular diagnostics company. It offers a portfolio of ultrasensitive tests covering prenatal genetic testing, cancer therapy selection, and response monitoring, which are based on its Quantitative Counting Templates (QCT) molecular counting platform. The company's product portfolio comprises UNITY, a portfolio of prenatal testing products that can conduct fetal risk analysis without requiring a paternal sample; Northstar Select, a ultrasensitive liquid biopsy test that provides insights into appropriate therapies for stage III or IV cancer patients; and Northstar Response, a tissue-free, pan-cancer, liquid biopsy test that measures several genomic loci uniquely methylated in cancer to provide insight into dynamic changes in therapy response.